Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1-3 prior lines of therapy

Clinical Lymphoma Myeloma and Leukemia(2023)

引用 0|浏览4
暂无评分
关键词
multiple myeloma,cilta-cel,lenalidomide-refractory
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要